Physician profile
Eva Varoqua
NPI 1003493792
$702.11
in general payments reported to CMS, 2019-2025
18 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $271 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.44 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $73.84 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $68.93 | 2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Stryker Corporation | $38.75 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lilly USA, LLC | $37.67 | 2024 | Jardiance, Mounjaro, Zepbound |
| Insightec,INC | $32.37 | 2024 | Exablate |
| Sanofi-Aventis U.S. LLC | $30.15 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.03 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $28.50 | 2024-2025 | Farxiga, Breztri |
| Dynavax Technologies Corporation | $27.18 | 2025 | Heplisav-B |
| Pfizer INC. | $23.81 | 2025 | |
| Daiichi Sankyo INC. | $23.66 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $20.11 | 2024 | |
| Corcept Therapeutics | $19.21 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.49 | 2024 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.02 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $14.27 | 2025 | Otezla, Repatha |
| Organon LLC | $11.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Varoqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.